LAUSR

diomyopathy during therapy with dabrafenib and trametinib. When myocarditis was first reported during treatment with dabrafenib and trametinib, a warning was published by the European Medicine Agency and myocarditis added to the serious side-effects. Differential diagnoses of myocarditis include infectious, immune-mediated and toxic causes. Granulomatous infiltration in the heart may be associated with rheumatic fever, metabolic disorders, sarcoidosis, Wegener’s granulomatosis, giant cell myocarditis and infectious diseases such as tuberculosis. In our case, autopsy confirmed inconspicuous heart valves, and no infectious focus was found. Moreover, sarcoidosis or rheumatoid arthritis was judged less probable, as there was no evidence of these generally systemic diseases. To recognize significant cardiac impairment during targeted therapy, echocardiography is recommended at baseline, after 1 month, and every 2–3 months thereafter. Our patient did not reveal any cardiac complaints or impairment. Increased CK is a common, frequently asymptomatic side effect of MEK inhibitors. However, based on our report we suggest to further investigate persistent elevation of CK during targeted therapy to rule out myocarditis. Altogether, our report contributes to expand knowledge about rare side-effects associated with contemporary oncological treatment.